GlaxoSmithKline (GB:GSK)
LSE:GSK
UK Market

GlaxoSmithKline Stock Analysis & Ratings

GB:GSK Stock Chart & Stats

Day’s Range1765.4p - 1785.2p
52-Week Range1,284.00p - 2,147.34p
Previous Close1,775p
Volume599.12K
Average Volume (3M)9.92M
Market Cap89.78B
P/E Ratio18.7
Beta0.72
Next EarningsJul 27, 2022
Dividend Yield0.31 (1.29%)
Smart Score8
EPS (TTM)1.02


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

GB:GSK FAQ

What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was 1284.00p and its highest was 2147.34p in the past 12 months.
    What is GlaxoSmithKline’s market cap?
    GlaxoSmithKline’s market cap is 89.78B.
      What is GlaxoSmithKline’s price target?
      The average price target for GlaxoSmithKline is 1,788.25p. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is 2,275.00p ,the lowest forecast is 1,400.00p. The average price target represents 1.26% Increase from the current price of 1,766p.
        What do analysts say about GlaxoSmithKline?
        GlaxoSmithKline’s analyst rating consensus is a ‘Hold. This is based on the ratings of 12 Wall Streets Analysts.
          When is GlaxoSmithKline’s upcoming earnings report date?
          GlaxoSmithKline’s upcoming earnings report date is Jul 27, 2022 which is in 62 days.
            How were GlaxoSmithKline’s earnings last quarter?
            GlaxoSmithKline released its earnings results on Apr 27, 2022. The company reported 32.8p earnings per share for the quarter, beating the consensus estimate of 29.8p by 3p.
              Is GlaxoSmithKline overvalued?
              According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
                Does GlaxoSmithKline pay dividends?
                GlaxoSmithKline pays a Annually dividend of 14p which represents an annual dividend yield of 1.29%. GlaxoSmithKline’s last Annually dividend payment was on Jul 01, 2022. GlaxoSmithKline’s upcoming ex-dividend date is May 19, 2022
                  What is GlaxoSmithKline’s EPS estimate?
                  GlaxoSmithKline’s EPS estimate for its next earnings report is not yet available.
                  How many shares outstanding does GlaxoSmithKline have?
                  GlaxoSmithKline has 5,080,000,000 shares outstanding.
                    What happened to GlaxoSmithKline’s price movement after its last earnings report?
                    GlaxoSmithKline reported an EPS of 32.8p in its last earnings report, beating expectations of 29.8p. Following the earnings report the stock price went up 2.417%.
                      Which hedge fund is a major shareholder of GlaxoSmithKline?
                      Currently, no hedge funds are holding shares in GB:GSK

                      ---

                      GlaxoSmithKline Stock Analysis

                      Smart Score
                      8
                      Outperform
                      1
                      2
                      3
                      4
                      5
                      6
                      7
                      8
                      9
                      10
                      Price Target
                      1,788.25p
                      ▲(1.26% Upside)
                      Hold

                      Analyst Forecast

                      Hold
                      Average Price Target: 1,788.25p

                      Blogger Sentiment

                      N/A
                      Currently Not Enough Data Available

                      Hedge Fund Holdings

                      N/A
                      Currently Not Enough Data Available

                      Insider Transactions

                      ▲ Bought Shares
                      Worth £1.7M over the Last 3 Months

                      Retail Investors

                      N/A
                      Currently Not Enough Data Available

                      News Sentiment

                      Neutral
                      Bullish 50% Bearish 50%

                      Technicals

                      SMA
                      Positive
                      20 days / 200 days
                      Momentum
                      37.66%
                      12-Months-Change

                      Fundamentals

                      Return on Equity
                      N/A
                      Trailing 12-Months
                      Asset Growth
                      N/A
                      Trailing 12-Months
                      The GlaxoSmithKline stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      GlaxoSmithKline

                      In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      BP p.l.c.
                      Vodafone
                      AstraZeneca
                      Unilever

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis